06.08.10
Lanx, Inc., a privately held spinal surgery device company, appointed Michael DeMane chairman and CEO. Michael Fulton, the company’s co-founder and former CEO will become chief technology officer, heading up the firm’s new technology initiatives.
DeMane is a medical device industry veteran, formerly serving in a variety of roles at Medtronic’s spinal division, most recently serving as chief operating officer. Prior to his roles at Medtronic Sofamor Danek, DeMane led Smith and Nephew Inc.’s orthopedic implant division and subsequently its commercial operations in Australia and New Zealand.
Fulton said DeMane’s decision to join the Broomfield, Colo.-based firm is “a testament to the innovation and dedication to technology that has driven our growth to date.”
According to DeMane, Lanx has maintained “considerable momentum based on an impressive product portfolio and pipeline,” crediting the company’s leadership with a “responsive, solutions-oriented culture, while maintaining a high level of ethics and integrity.”
Lanx is backed by a group of institutional investors, including Chicago Growth Partners, Goldman Sachs Private Equity Opportunities Fund, Noro-Moseley Partners and Oakwood Medical Investors.
The company also recently appointed Shawn McCormick to its board of directors. McCormick currently is senior vice president and chief financial officer of ev3, Inc., which recently was purchased by Covidien plc.
Lanx was founded in 2003.
DeMane is a medical device industry veteran, formerly serving in a variety of roles at Medtronic’s spinal division, most recently serving as chief operating officer. Prior to his roles at Medtronic Sofamor Danek, DeMane led Smith and Nephew Inc.’s orthopedic implant division and subsequently its commercial operations in Australia and New Zealand.
Fulton said DeMane’s decision to join the Broomfield, Colo.-based firm is “a testament to the innovation and dedication to technology that has driven our growth to date.”
According to DeMane, Lanx has maintained “considerable momentum based on an impressive product portfolio and pipeline,” crediting the company’s leadership with a “responsive, solutions-oriented culture, while maintaining a high level of ethics and integrity.”
Lanx is backed by a group of institutional investors, including Chicago Growth Partners, Goldman Sachs Private Equity Opportunities Fund, Noro-Moseley Partners and Oakwood Medical Investors.
The company also recently appointed Shawn McCormick to its board of directors. McCormick currently is senior vice president and chief financial officer of ev3, Inc., which recently was purchased by Covidien plc.
Lanx was founded in 2003.